Harm Reduction Services

1. Opioid Substitution Treatment Service

• OST Service Specification
• Service User and Provider Agreement (Generic)
• Belfast HSC Trust "Substitute Prescribing Agreement"
• Oromucosal Buprenorphine : Espranor®
• References

1. Opioid Substitution Treatment : Northern Ireland Supplementary Guidance for Community Pharmacists 2019 (Version 1.1)  Updated January 2021
2. Opioid Substitution Treatment : Cover letter issued with Northern Ireland Supplementary Guidance for Community Pharmacists 2019 (July 2019)
3. Drug Misuse and Dependence : UK Guidelines on Clinical Management 2017
4. Learning from Serious Adverse Incident (SAI) : Action Required when a Patient Receiving Oral Substitution Treatment (OST) Misses Doses or Circumstances Change (Jan 2021)
5. Opioid Substitution Treatment : Addendum to NI Supplementary Guidance for Community Pharmacists 2019 (Jan 2021)

https://www.gov.uk/government/publications/drug-misuse-and-dependence-uk-guidelines-on-clinical-management

 

 

2. Needle and Syringe Exchange Service

• NSES Service Specification (2018)
• Guidance for Community Pharmacy Needle Exchange (2017)
• List of Community Pharmacy Providers (2020)
• Low Threshold Services (2017)
• Needle and Syringe Provision : Self Select Order Form (PHA,2020)
• Needle and Syringe Provision : NI Guide to Needle Exchange Pack Contents
• References

1. Needle and Syringe Exchange Scheme Leaflet
2. Annual Report of the Needle & Syringe Exchange Scheme

 

 

3.Naloxone

• References

1. "Widening the availability of Naloxone" Guidance 2017

   https://www.gov.uk/government/publications/widening-the-availability-of-naloxone/widening-the-availability-of-naloxone

       2.  Take Home Naloxone

http://www.publichealth.hscni.net/publications/take-home-naloxone

Contents

• Oromucosal Buprenorphine : Espranor